Vasodilating versus first-generation β-blockers for cardiovascular protection (Q37995858)

26 August 2017

title

Vasodilating versus first-generation β-blockers for cardiovascular protection (English)

1 reference

26 August 2017

1 reference

2

Carl J Lavie

1 reference

26 August 2017

Hassan Fares

1

1 reference

26 August 2017

Hector O Ventura

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

26 August 2017

published in

Postgraduate Medicine

1 reference

26 August 2017

volume

124

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

7-15

1 reference

Obesity and hypertension: two epidemics or one?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Beta-blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Arterial stiffness, hypertension, and rational use of nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Benefits of inpatient initiation of beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Nebivolol: the somewhat-different beta-adrenergic receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Carvedilol in hypertension treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Beta blockers in the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Cardiovascular protection using beta-blockers: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Arterial Stiffness, Its Assessment, Prognostic Value, and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Beta-blockers and coronary flow reserve: the importance of a vasodilatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Hypertension and antihypertensive therapy in Hispanics and Mexican Americans living in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

Normal Vascular Aging: Differential Effects on Wave Reflection and Aortic Pulse Wave Velocity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.03.2532

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.03.2532

1 reference

26 August 2017

1 reference